Anixa Biosciences’ (ANIX) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research report released on Wednesday,Benzinga reports. The firm currently has a $10.00 target price on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Anixa Biosciences in a research report on Tuesday, November 19th.

Anixa Biosciences Price Performance

ANIX opened at $2.97 on Wednesday. The firm has a market capitalization of $95.63 million, a PE ratio of -7.62 and a beta of 0.90. The business’s 50-day moving average is $2.77 and its two-hundred day moving average is $3.04. Anixa Biosciences has a 1 year low of $2.07 and a 1 year high of $5.00.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Friday, January 10th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. As a group, sell-side analysts expect that Anixa Biosciences will post -0.46 EPS for the current year.

Insider Buying and Selling

In related news, Director Lewis H. Titterton, Jr. purchased 10,000 shares of the firm’s stock in a transaction on Friday, January 17th. The stock was acquired at an average price of $2.57 per share, with a total value of $25,700.00. Following the completion of the acquisition, the director now owns 922,334 shares in the company, valued at approximately $2,370,398.38. This represents a 1.10 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Amit Kumar acquired 43,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were bought at an average price of $2.23 per share, with a total value of $95,890.00. Following the completion of the purchase, the chief executive officer now directly owns 559,925 shares of the company’s stock, valued at approximately $1,248,632.75. This trade represents a 8.32 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased 68,289 shares of company stock worth $157,101 in the last three months. Corporate insiders own 22.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. International Assets Investment Management LLC lifted its holdings in shares of Anixa Biosciences by 170.0% during the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after purchasing an additional 23,800 shares during the period. Tyler Stone Wealth Management lifted its stake in Anixa Biosciences by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after acquiring an additional 21,008 shares during the period. Virtu Financial LLC acquired a new stake in shares of Anixa Biosciences in the third quarter worth $34,000. Finally, Westside Investment Management Inc. raised its holdings in shares of Anixa Biosciences by 151.8% during the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after purchasing an additional 21,100 shares during the last quarter. 29.13% of the stock is owned by institutional investors and hedge funds.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.